Biomarker Development Suppliers Serving Monaco

SCIEX empowers you to solve the most impactful analytical challenges in quantitation and characterization in environmental testing. With groundbreaking innovation and outstanding reliability and support, SCIEX has been at the forefront of the field ...

At Alithea Genomics we are committed to developing solutions that simplify and streamline the generation of 'big RNA data', which we believe will constitute the foundation of tomorrow's research and medicine. Our technologies enable our clients to ...

When we looked at the decision making landscape in organizations and observed that the available technologies and models were helping make decisions but with fixed cycles of information processing, running in batches, with little flexibility and ...

Biomedica is part of the AddLife Group, a publicly traded parent company consisting of various subsidiaries in the Life Science and Medical Device fields. AddLife strives to improve people’s lives by being a leading, value creating player in Life ...

Nirmidas Biotech was founded in September of 2013. We are a member of the Janssen Labs (JLABS) and QB3 programs, the Stanford StartX Med Program, and the MIT Industrial Liaison Program (MIT ILP). We are also a StartX Med COVID-19 Task Force Company ...

The Actlabs Group of Companies provides contract analytical services covering all aspects of analysis from academic research applications to routine quality control functions. We provide our services to many fields, including Geochemical, ...

Invicro is an integral part of the REALM IDx, Inc. group, which aims to accelerate personalized medicine, discover novel therapeutic targets and develop innovative therapeutic technologies for unmet medical needs. As a global research partner to the ...

Olink Proteomics is a Swedish company dedicated to innovation, quality, rigor and transparency, providing outstanding products and services for human protein biomarker discovery. Our groundbreaking Olink panels for precision proteomics help ...

ACD - a Bio-Techne brand, shortens the path to personalized medicine and enables research, drug development and clinical applications by unlocking the power of RNA. ACD is a leader in the emerging field of molecular pathology, developing cell- and ...

We make software that transforms medical data into deeper insight. Our AI technology takes medical intelligence to the next level: data-driven medicine. We aim to solve the most critical issues in cancer care today: reduce medical cost and prolong ...

Tempo Bioscience, Inc (Tempo) develops human stem cells (human iPSC technology) based cell models and biosensor enabling technologies for preclinical drug discovery & development, biobanking, in vitro diagnostics, and biomarker development. Our ...

Artificial intelligence for every step of pharmaceutical research and development. Our mission is to accelerate drug discovery and drug development by continuously inventing and deploying new artificial intelligence technologies. We provide AI ...

Our mission is to make it easier to analyze the huge amounts of complex data that are generated by innovations in the fields of genetics and proteomics. We do this by providing powerful visualization-based bioinformatics data analysis tools for ...

Yashraj Biotech Limited manufactures a wide range of high pure biomarkers in the form of native and recombinant proteins that are used by the diagnostic industry as controls, calibrators and immunogens. YBL has been the preferred partner of most of ...

Oncimmune is a leading immuno diagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Our growing range of diagnostic products can detect early-stage cancer and our service-based ...

BioSensics is a global leader in development of wearable sensors and digital platforms for clinical trials, patient monitoring and health assessment. BioSensics was founded in 2007 by three scientists from Harvard University with a vision of ...

Cellworks’ mission is to serve patients through advances in personalized medicine that significantly improve treatment success. We achieve better outcomes by predicting a successful match between patients and drug therapies – their Therapy Response ...

Good diagnostic products require high-quality human biomaterials (serums, standards, control samples, purified proteins, and antibodies). Out of this need, we founded ourselves in 1997 as a spin-off of the research department of B.R.A.H.M.S. AG. ...

20/20 GeneSystems (“20/20”) is focused on on reducing cancer deaths worldwide through its years of experience in the development and use of cancer biomarker test development. By leveraging this expertise and combining it with advanced machine ...

By launching first-in-market biomarker tests and developing digital biomarkers for the continuous monitoring of disease, we support clinicians in their effort to provide exceptional care. Our technologies will empower clinician decision making and ...